Shots:
Oncolytics has reported initial data from a preclinical study assessing pelareorep, a systemically active immunotherapy, in combination with RAS inhibitor modalities, which showed greater anti-tumor activity in a solid tumor model vs either therapy alone
Based on the findings, Oncolytics is planning additional studies of the combination in pancreatic ductal adenocarcinoma & colorectal cancer…
